Fig. 2
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40880-016-0086-2/MediaObjects/40880_2016_86_Fig2_HTML.gif)
Overall survival (OS) curves of EGFR-mutated patients treated with TKIs. a OS curves of patients with EGFR 19 del and L858R mutation who received first-line TKI therapy (34.9 vs. 37.5Â months, PÂ =Â 0.566); b OS curves of patients with the EGFR 19 del and L858R mutation who received second-line or greater TKI therapy (26.7 vs. 23.8Â months, PÂ =Â 0.256)